Delivery Order SPE2DB24D2003-SPE2DB25FXLD6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $16,991.63 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units). This competitively awarded, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of September 15, 2025. The delivery order was issued on September 12, 2025, with performance to take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,436.87 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed price contract. The order, issued on August 20, 2025, with an ultimate completion date of August 21, 2025, represents a non-competitive set-aside delivery order for pharmaceutical products to support federal medical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count packages) valued at $3,152.98 under a firm fixed-price contract. The award was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside delivery order will be fulfilled at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is the prime...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,444.54 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed price contract. The award was made on August 25, 2025, with an ultimate completion date of August 26, 2025, and represents a competitively awarded, non-set-aside procurement. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,888.67 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60 count) on August 19, 2025, with a completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order draws from AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,839.36 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed price contract. The award was issued on August 28, 2025, with an ultimate completion date of August 29, 2025, and represents a non-set-aside competitive procurement. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg with a ceiling value of $12,882.51 on August 15, 2025. This competitively awarded, firm fixed-price delivery order is due for completion by August 18, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract carries no set-aside designation, reflecting the vendor's demonstrated capability to meet federal procurement requirements...
- The Defense Logistics Agency awarded a delivery order valued at $3,934.86 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on April 21, 2025, with an ultimate completion date of April 22, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's larger contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $84,204.97 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on June 2, 2025, with an ultimate completion date of June 3, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child delivery order issued against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $3,707.42 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single transaction within AmerisourceBergen's...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLD6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,785.70 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) under a firm fixed price contract. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. This delivery order represents a non-competitive purchase executed under an existing contract vehicle and will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a primary pharmaceutical distributor for federal medical procurement, supplying a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. The company's extensive portfolio of federal contracts demonstrates its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains on behalf of the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 7/28/25 |